ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

TCRT Alaunos Therapeutics Inc

1.81
-0.05 (-2.69%)
Mar 28 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 70,165
Bid Price 1.75
Ask Price 2.04
News -
Day High 1.88

Low
0.66

52 Week Range

High
10.50

Day Low 1.80
Share Name Share Symbol Market Stock Type
Alaunos Therapeutics Inc TCRT NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
-0.05 -2.69% 1.81 19:00:00
Open Price Low Price High Price Close Price Previous Close
1.85 1.80 1.88 1.81 1.86
Trades Shares Traded VWAP Financial Volume Average Volume 52 Week Range
572 70,165 US$ 1.84 US$ 129,133 - 0.66 - 10.50
Last Trade Type Quantity Price Currency
17:57:08 5 US$ 1.88 USD

Alaunos Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
29.36M 16.04M - 2.92M -37.73M -2.35 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Alaunos Therapeutics News

Date Time Source News Article
2/28/202420:46Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of..
2/22/202415:44Edgar (US Regulatory)Form 8-K - Current report
2/20/202415:05Edgar (US Regulatory)Form 8-K - Current report
2/14/202411:43Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial..
2/13/202415:58Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial..
1/29/202407:45Edgar (US Regulatory)Form 8-K - Current report
1/23/202416:47Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
1/22/202415:30Edgar (US Regulatory)Form 8-K - Current report
1/03/202416:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
1/03/202416:25Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of..
1/02/202407:00Edgar (US Regulatory)Form 8-K - Current report
12/28/202315:30Edgar (US Regulatory)Form 8-K - Current report
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No TCRT Message Board. Create One! See More Posts on TCRT Message Board See More Message Board Posts

Historical TCRT Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week1.772.031.761.9059,6170.042.26%
1 Month2.322.321.511.8864,761-0.51-21.98%
3 Months1.263.2851.202.192,434,1300.5543.65%
6 Months1.953.2850.661.393,867,664-0.14-7.18%
1 Year10.5010.500.662.052,578,200-8.69-82.76%
3 Years12.9960.150.6610.992,511,197-11.18-86.07%
5 Years12.9960.150.6610.992,511,197-11.18-86.07%

Alaunos Therapeutics Description

Ziopharm Oncology Inc is registered with the U.S. Security and Exchange Commission and incorporated in the state of Delaware. Ziopharm Oncology Inc is primarely in the business of pharmaceutical preparations. For financial reporting, their fiscal year ends on December 31st. This page includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by Ziopharm Oncology Inc. ZIOPHARM Oncology Inc is a biotechnology company that acquires, develops, and commercializes cancer therapies. Its preclinical and clinical pipeline focuses on treating hematological and solid tumor malignancies using cellular therapeutics. Ziopharm engages in gene therapy systems with its partner Intrexon and collaborators at the University of Texas. To fund the development of its product candidates, the company engages in contractual arrangements with licensing partners both in the United States and abroad.

Your Recent History

Delayed Upgrade Clock